These guidelines have been developed for scientific purpose with the main aim to guide the regulatory authority for evaluating probiotic products in our country.
The flip book is for pre-deployment trainings for Ebola response, and is based on frequently asked questions about Ebola virus disease (EVD):
What is Ebola virus disease?
How do people become infected with EVD?
Why WHO is focusing on safe and dignified burials of people who have died ...from Ebola?
Who is most at risk?
What are the symptoms of Ebola infection?
What treatment is available for Ebola?
more
The WHO Guidelines for malaria bring together the Organization’s most up-to-date recommendations for malaria in one user-friendly and easy-to-navigate online platform.
The WHO Guidelines for malaria supersedes 2 previous WHO publications: the Guidelines for the treatment of malaria, third e...dition and the Guidelines for malaria vector control. Recommendations on malaria will continue to be reviewed and, where appropriate, updated based on the latest available evidence. Any updated recommendations will always display the date of the most recent revision in the MAGICapp platform. With each update, a new PDF version of the consolidated guidelines will also be available for download on the WHO website.
This version of the Guidelines includes updates to the case management of malaria, specifically the addition of new molecules for the treatment of uncomplicated malaria and optimization of the dosage regimen for anti-relapse treatment, along with updates on the use of antimalarial medicines in special risk populations including pregnant women.
more
Clinical Infectious Diseases 2010; 50:291–322
There is an urgent need for safer, simpler, more efficacious and accessible treatment regimens for all forms of TB. The development of Target Product Profiles for TB treatment regimens (referred to as Target Regimen Profiles or TRPs) seeks to guide the drug development process towards important regi...men characteristics corresponding to the needs of end-users.
more
Clinical guideline | Published: 11 January 2012 | nice.org.uk/guidance/cg137
The purpose of these guidelines is to help health workers to participate in the process of continuous surveillance of safety and efficacy of the pharmaceutical products which are used in clinical practice, thus help to achieve the ultimate goal to make safer and more effective treatment available to... patients. This guideline addresses specifically the issues on what to report, why to report, when to report, where to report and how to report.
more
This booklet is recommended for all health workers who diagnose and treat leprosy, especially those at the first referral level such as a health centre. It contains more detail than the WHO Guide to Eliminate Leprosy as a Public Health Problem. The Guide gives practical advice on how to diagnose lep...rosy and how to give the correct treatment, and basic information on how to recognise and manage leprosy reactions.e
more
2nd edition. These guidelines include several notable changes from the first edition. For cutaneous leishmaniasis, ketoconazole has been removed from the list of treatment options; the number of Leishmania species for which there is strong evidence for the efficacy of miltefosine has increased from ...two to four; and the recommendation for intralesional antimonials is now strong. For mucosal leishmaniasis there is now a strong recommendation for use of pentavalent antimonials with or without oral pentoxifylline. For visceral leishmaniasis, the strong recommendations for use of pentavalent antimonials and amphotericin B deoxycholate are now conditional.
more